{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T19:31:52Z","timestamp":1770319912125,"version":"3.49.0"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T00:00:00Z","timestamp":1770249600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T00:00:00Z","timestamp":1770249600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Pain Headache Rep"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s11916-025-01432-w","type":"journal-article","created":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T06:12:02Z","timestamp":1770271922000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Perioperative Management of Patients on Buprenorphine"],"prefix":"10.1007","volume":"30","author":[{"given":"Nalini","family":"Vadivelu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicholas","family":"Mydlo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"Dextras","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica","family":"Ng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew","family":"Silverman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gopal","family":"Kodumudi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sean","family":"Chowdhari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberta","family":"Hines","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donna -Ann","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Hickey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,5]]},"reference":[{"key":"1432_CR1","unstructured":"Ahmad FB, Cisewski JA, Rossen LM, Sutton P. Provisional Drug Overdose Death Counts: National Center for Health Statistics; 2024 [Available from: https:\/\/www.cdc.gov\/nchs\/nvss\/vsrr\/drug-overdose-data.htm"},{"key":"1432_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.dadr.2022.100052","author":"KM Keyes","year":"2022","unstructured":"Keyes KM, Rutherford C, Hamilton A, Barocas JA, Gelberg KH, Mueller PP, et al. What is the prevalence of and trend in opioid use disorder in the United States from 2010 to 2019? Using multiplier approaches to estimate prevalence for an unknown population size. Drug Alcohol Depend Rep. 2022. https:\/\/doi.org\/10.1016\/j.dadr.2022.100052.","journal-title":"Drug Alcohol Depend Rep"},{"issue":"8","key":"1432_CR3","doi-asserted-by":"publisher","first-page":"e2327488","DOI":"10.1001\/jamanetworkopen.2023.27488","volume":"6","author":"CM Jones","year":"2023","unstructured":"Jones CM, Han B, Baldwin GT, Einstein EB, Compton WM. Use of medication for opioid use disorder among adults with past-year opioid use disorder in the US, 2021. JAMA Netw Open. 2023;6(8):e2327488.","journal-title":"JAMA Netw Open"},{"issue":"7","key":"1432_CR4","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1111\/dar.13129","volume":"39","author":"CL Arfken","year":"2020","unstructured":"Arfken CL, Owens DD, Greenwald MK. US national treatment admissions with opioids and benzodiazepines. Drug Alcohol Rev. 2020;39(7):862\u20139.","journal-title":"Drug Alcohol Rev"},{"issue":"6","key":"1432_CR5","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1007\/s40263-019-00637-z","volume":"33","author":"M Shulman","year":"2019","unstructured":"Shulman M, Wai JM, Nunes EV. Buprenorphine treatment for opioid use disorder: an overview. CNS Drugs. 2019;33(6):567\u201380.","journal-title":"CNS Drugs"},{"issue":"7","key":"1432_CR6","doi-asserted-by":"publisher","first-page":"661","DOI":"10.2165\/00003088-200544070-00001","volume":"44","author":"A Elkader","year":"2005","unstructured":"Elkader A, Sproule B. Buprenorphine: clinical pharmacokinetics in the treatment of opioid dependence. Clin Pharmacokinet. 2005;44(7):661\u201380.","journal-title":"Clin Pharmacokinet"},{"issue":"12","key":"1432_CR7","first-page":"29","volume":"2","author":"C Welsh","year":"2005","unstructured":"Welsh C, Valadez-Meltzer A. Buprenorphine: a (relatively) new treatment for opioid dependence. Psychiatry (Edgmont). 2005;2(12):29\u201339.","journal-title":"Psychiatry (Edgmont)"},{"issue":"11","key":"1432_CR8","doi-asserted-by":"publisher","first-page":"2000","DOI":"10.1038\/sj.npp.1300251","volume":"28","author":"MK Greenwald","year":"2003","unstructured":"Greenwald MK, Johanson CE, Moody DE, Woods JH, Kilbourn MR, Koeppe RA, et al. Effects of buprenorphine maintenance dose on mu-opioid receptor availability, plasma concentrations, and antagonist Blockade in heroin-dependent volunteers. Neuropsychopharmacology. 2003;28(11):2000\u20139.","journal-title":"Neuropsychopharmacology"},{"issue":"5","key":"1432_CR9","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1093\/bja\/ael051","volume":"96","author":"A Dahan","year":"2006","unstructured":"Dahan A, Yassen A, Romberg R, Sarton E, Teppema L, Olofsen E, et al. Buprenorphine induces ceiling in respiratory depression but not in analgesia. Br J Anaesth. 2006;96(5):627\u201332.","journal-title":"Br J Anaesth"},{"issue":"5","key":"1432_CR10","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1097\/MJT.0b013e3181be0804","volume":"17","author":"H Kornfeld","year":"2010","unstructured":"Kornfeld H, Manfredi L. Effectiveness of full agonist opioids in patients stabilized on buprenorphine undergoing major surgery: a case series. Am J Ther. 2010;17(5):523\u20138.","journal-title":"Am J Ther"},{"issue":"2","key":"1432_CR11","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1177\/0310057X1304100212","volume":"41","author":"PE Macintyre","year":"2013","unstructured":"Macintyre PE, Russell RA, Usher KA, Gaughwin M, Huxtable CA. Pain relief and opioid requirements in the first 24 hours after surgery in patients taking buprenorphine and methadone opioid substitution therapy. Anaesth Intensive Care. 2013;41(2):222\u201330.","journal-title":"Anaesth Intensive Care"},{"issue":"9","key":"1432_CR12","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1093\/pm\/pnaa020","volume":"21","author":"A Quaye","year":"2020","unstructured":"Quaye A, Potter K, Roth S, Acampora G, Mao J, Zhang Y. Perioperative continuation of buprenorphine at low-moderate doses was associated with lower postoperative pain scores and decreased outpatient opioid dispensing compared with buprenorphine discontinuation. Pain Med. 2020;21(9):1955\u201360.","journal-title":"Pain Med"},{"key":"1432_CR13","doi-asserted-by":"crossref","unstructured":"Gudin J, Fudin JA Narrative Pharmacological Review of Buprenorphine: A Unique Opioid for the Treatment of Chronic Pain. Pain Ther., Infantino R, Mattia C, Locarini P, Pastore AL, Maione S, Luongo L. Buprenorphine: Far Beyond the Ceiling. Biomolecules. 2021;11(6).","DOI":"10.3390\/biom11060816"},{"key":"1432_CR14","doi-asserted-by":"crossref","unstructured":"Infantino R, Mattia C, Locarini P, Pastore AL, Maione S, Luongo L. Buprenorphine: Far Beyond the \"Ceiling\". Biomolecules. 2021;11(6).","DOI":"10.3390\/biom11060816"},{"key":"1432_CR15","doi-asserted-by":"publisher","DOI":"10.3390\/ph16101397","author":"LJ Pande","year":"2023","unstructured":"Pande LJ, Arnet RE, Piper BJ. An examination of the complex pharmacological properties of the non-selective opioid modulator buprenorphine. Pharmaceuticals (Basel). 2023. https:\/\/doi.org\/10.3390\/ph16101397.","journal-title":"Pharmaceuticals (Basel)"},{"issue":"4","key":"1432_CR16","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1124\/mol.110.066613","volume":"78","author":"J McPherson","year":"2010","unstructured":"McPherson J, Rivero G, Baptist M, Llorente J, Al-Sabah S, Krasel C, et al. \u00b5-opioid receptors: correlation of agonist efficacy for signalling with ability to activate internalization. Mol Pharmacol. 2010;78(4):756\u201366.","journal-title":"Mol Pharmacol"},{"key":"1432_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2019.107718","volume":"166","author":"MF Pedersen","year":"2020","unstructured":"Pedersen MF, Wr\u00f3bel TM, M\u00e4rcher-R\u00f8rsted E, Pedersen DS, M\u00f8ller TC, Gabriele F, et al. Biased agonism of clinically approved \u00b5-opioid receptor agonists and TRV130 is not controlled by binding and signaling kinetics. Neuropharmacology. 2020;166:107718.","journal-title":"Neuropharmacology"},{"key":"1432_CR18","first-page":"859","volume":"8","author":"IK Khanna","year":"2015","unstructured":"Khanna IK, Pillarisetti S. Buprenorphine - an attractive opioid with underutilized potential in treatment of chronic pain. J Pain Res. 2015;8:859\u201370.","journal-title":"J Pain Res"},{"issue":"3","key":"1432_CR19","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.ejpain.2008.04.011","volume":"13","author":"HG Kress","year":"2009","unstructured":"Kress HG. Clinical update on the pharmacology, efficacy and safety of transdermal buprenorphine. Eur J Pain. 2009;13(3):219\u201330.","journal-title":"Eur J Pain"},{"issue":"3","key":"1432_CR20","doi-asserted-by":"publisher","DOI":"10.52965\/001c.37517","volume":"10","author":"S Poliwoda","year":"2022","unstructured":"Poliwoda S, Noor N, Jenkins JS, Stark CW, Steib M, Hasoon J, et al. Buprenorphine and its formulations: a comprehensive review. Health Psychol Res. 2022;10(3):37517.","journal-title":"Health Psychol Res"},{"key":"1432_CR21","unstructured":"BUPRENEX\u00ae (buprenorphine hydrochloride). [package insert]. Hull, England, HU8 7DS:Reckitt benckiser healthcare. UK) Ltd.; 2019."},{"key":"1432_CR22","unstructured":"BUTRANS\u00ae (buprenorphine) [package insert]. Stamford, CT 06901\u2009\u2013\u20093431:Purdue Pharma L.P.;2014."},{"key":"1432_CR23","unstructured":"BELBUCA(TM). (buprenorphine) [package insert]. Malvern, PA 19355:Endo Pharmaceuticals Inc.;2015."},{"issue":"6","key":"1432_CR24","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1097\/00000539-200106000-00050","volume":"92","author":"JA May","year":"2001","unstructured":"May JA, White HC, Leonard-White A, Warltier DC, Pagel PS. The patient recovering from alcohol or drug addiction: special issues for the anesthesiologist. Anesth Analg. 2001;92(6):1601\u20138.","journal-title":"Anesth Analg"},{"issue":"5","key":"1432_CR25","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1111\/add.14114","volume":"113","author":"KM Bogdanowicz","year":"2018","unstructured":"Bogdanowicz KM, Stewart R, Chang CK, Shetty H, Khondoker M, Day E, et al. Excess overdose mortality immediately following transfer of patients and their care as well as after cessation of opioid substitution therapy. Addiction. 2018;113(5):946\u201351.","journal-title":"Addiction"},{"key":"1432_CR26","doi-asserted-by":"crossref","unstructured":"Bentzley BS, Barth KS, Back SE, Book SW. Discontinuation of buprenorphine maintenance therapy: perspectives and outcomes. J Subst Abuse Treat., Kohan L, Potru S, Barreveld AM, Sprintz M, Lane O, Aryal A et al. Buprenorphine management in the perioperative period: educational review and recommendations from a multisociety expert panel. Reg Anesth Pain Med. 2021;46(10):840\u2009\u2013\u200959.","DOI":"10.1136\/rapm-2021-103007"},{"issue":"10","key":"1432_CR27","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1136\/rapm-2021-103007","volume":"46","author":"L Kohan","year":"2021","unstructured":"Kohan L, Potru S, Barreveld AM, Sprintz M, Lane O, Aryal A, et al. Buprenorphine management in the perioperative period: educational review and recommendations from a multisociety expert panel. Reg Anesth Pain Med. 2021;46(10):840-59.","journal-title":"Reg Anesth Pain Med"},{"key":"1432_CR28","unstructured":"Medications for Opioid Use Disorder. For Healthcare and Addiction Professionals, Policymakers, Patients, and Families: Updated 2021. 2018."},{"issue":"6","key":"1432_CR29","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1097\/ALN.0000000000001633","volume":"126","author":"TA Anderson","year":"2017","unstructured":"Anderson TA, Quaye ANA, Ward EN, Wilens TE, Hilliard PE, Brummett CM. To stop or not, that is the question: acute pain management for the patient on chronic buprenorphine. Anesthesiology. 2017;126(6):1180\u20136.","journal-title":"Anesthesiology"},{"issue":"12","key":"1432_CR30","doi-asserted-by":"publisher","first-page":"2998","DOI":"10.1007\/s11606-021-07118-4","volume":"37","author":"JJ Wyse","year":"2022","unstructured":"Wyse JJ, Herreid-O\u2019Neill A, Dougherty J, Shull S, Mackey K, Priest KC, et al. Perioperative management of Buprenorphine\/Naloxone in a Large, National health care system: a retrospective cohort study. J Gen Intern Med. 2022;37(12):2998\u20133004.","journal-title":"J Gen Intern Med"},{"key":"1432_CR31","doi-asserted-by":"crossref","unstructured":"Quaye A, Mardmomen N, Mogren G, Ibrahim Y, Richard J, Zhang Y. Current State of Perioperative Buprenorphine Management-A National Provider Survey. J Addict Med., Sandbrink F, Murphy JL, Johansson M, Olson JL, Edens E, Clinton-Lont J et al. The Use of Opioids in the Management of Chronic Pain: Synopsis of the 2022 Updated U.S. Department of Veterans Affairs and U.S. Department of Defense Clinical Practice Guideline. Ann Intern Med. 2023;176(3):388\u2009\u2013\u200997.","DOI":"10.7326\/M22-2917"},{"issue":"3","key":"1432_CR32","doi-asserted-by":"publisher","first-page":"388","DOI":"10.7326\/M22-2917","volume":"176","author":"F Sandbrink","year":"2023","unstructured":"Sandbrink F, Murphy JL, Johansson M, Olson JL, Edens E, Clinton-Lont J, et al. The Use of Opioids in the Management of Chronic Pain: Synopsis of the 2022 Updated U.S. Department of Veterans Affairs and U.S. Department of Defense Clinical Practice Guideline. Ann Intern Med. 2023;176(3):388-97.","journal-title":"Ann Intern Med"},{"key":"1432_CR33","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.2147\/JPR.S305146","volume":"14","author":"M Hale","year":"2021","unstructured":"Hale M, Garofoli M, Raffa RB. Benefit-risk analysis of buprenorphine for pain management. J Pain Res. 2021;14:1359\u201369.","journal-title":"J Pain Res"},{"key":"1432_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.drugalcdep.2014.07.035","volume":"144","author":"MK Greenwald","year":"2014","unstructured":"Greenwald MK, Comer SD, Fiellin DA. Buprenorphine maintenance and mu-opioid receptor availability in the treatment of opioid use disorder: implications for clinical use and policy. Drug Alcohol Depend. 2014;144:1\u201311.","journal-title":"Drug Alcohol Depend"},{"issue":"2","key":"1432_CR35","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1097\/AJP.0b013e31815ca2b4","volume":"24","author":"HA Heit","year":"2008","unstructured":"Heit HA, Gourlay DL. Buprenorphine: new tricks with an old molecule for pain management. Clin J Pain. 2008;24(2):93\u20137.","journal-title":"Clin J Pain"},{"issue":"2","key":"1432_CR36","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.pmr.2020.02.001","volume":"31","author":"GD Rudolf","year":"2020","unstructured":"Rudolf GD. Buprenorphine in the treatment of chronic pain. Phys Med Rehabil Clin N Am. 2020;31(2):195\u2013204.","journal-title":"Phys Med Rehabil Clin N Am"},{"key":"1432_CR37","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.2147\/JPR.S132595","volume":"10","author":"S Silverman","year":"2017","unstructured":"Silverman S, Raffa RB, Cataldo MJ, Kwarcinski M, Ripa SR. Use of immediate-release opioids as supplemental analgesia during management of moderate-to-severe chronic pain with buprenorphine transdermal system. J Pain Res. 2017;10:1255\u201363.","journal-title":"J Pain Res"},{"issue":"3 Suppl","key":"1432_CR38","doi-asserted-by":"publisher","first-page":"ES59","DOI":"10.36076\/ppj.2012\/15\/ES59","volume":"15","author":"J Daitch","year":"2012","unstructured":"Daitch J, Frey ME, Silver D, Mitnick C, Daitch D, Pergolizzi J. Conversion of chronic pain patients from full-opioid agonists to sublingual buprenorphine. Pain Physician. 2012;15(3 Suppl):ES59-66.","journal-title":"Pain Physician"},{"issue":"12","key":"1432_CR39","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1111\/pme.12520","volume":"15","author":"D Daitch","year":"2014","unstructured":"Daitch D, Daitch J, Novinson D, Frey M, Mitnick C, Pergolizzi J. Conversion from high-dose full-opioid agonists to sublingual buprenorphine reduces pain scores and improves quality of life for chronic pain patients. Pain Med. 2014;15(12):2087\u201394.","journal-title":"Pain Med"},{"issue":"11","key":"1432_CR40","doi-asserted-by":"publisher","first-page":"2961","DOI":"10.1007\/s00586-017-5213-5","volume":"26","author":"HJ Kim","year":"2017","unstructured":"Kim HJ, Ahn HS, Nam Y, Chang BS, Lee CK, Yeom JS. Comparative study of the efficacy of transdermal buprenorphine patches and prolonged-release tramadol tablets for postoperative pain control after spinal fusion surgery: a prospective, randomized controlled non-inferiority trial. Eur Spine J. 2017;26(11):2961\u20138.","journal-title":"Eur Spine J"},{"key":"1432_CR41","volume":"65","author":"FH Kiabi","year":"2021","unstructured":"Kiabi FH, Emadi SA, Shafizad M, Jelodar AG, Deylami H. The effect of preoperative sublingual buprenorphine on postoperative pain after lumbar discectomy: a randomized controlled trial. Ann Med Surg (Lond). 2021;65:102347.","journal-title":"Ann Med Surg (Lond)"},{"key":"1432_CR42","doi-asserted-by":"publisher","first-page":"2552","DOI":"10.14260\/Jemds\/2017\/552","volume":"6","author":"D Mondal","year":"2017","unstructured":"Mondal D, Pathak DG, Begum I, Pegu B, Chauhan RC. A comparative study between epidural buprenorphine and epidural tramadol for postoperative analgesia in patients undergoing lower abdominal surgeries. J Evol Med Dent Sci. 2017;6:2552.","journal-title":"J Evol Med Dent Sci"},{"issue":"4","key":"1432_CR43","doi-asserted-by":"publisher","first-page":"496","DOI":"10.4103\/0970-9185.169072","volume":"31","author":"S Patil","year":"2015","unstructured":"Patil S, Debata D, Doshi C, Vyas V, Sinha S. Effect of buprenorphine as an adjunct with plain local anesthetic solution in supraclavicular brachial plexus block on quality and duration of postoperative analgesia. J Anaesthesiol Clin Pharmacol. 2015;31(4):496\u2013500.","journal-title":"J Anaesthesiol Clin Pharmacol"},{"issue":"6","key":"1432_CR44","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1111\/jcpt.12196","volume":"39","author":"RB Raffa","year":"2014","unstructured":"Raffa RB, Haidery M, Huang HM, Kalladeen K, Lockstein DE, Ono H, et al. The clinical analgesic efficacy of buprenorphine. J Clin Pharm Ther. 2014;39(6):577\u201383.","journal-title":"J Clin Pharm Ther"},{"issue":"4","key":"1432_CR45","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1016\/j.bja.2017.11.086","volume":"120","author":"LD White","year":"2018","unstructured":"White LD, Hodge A, Vlok R, Hurtado G, Eastern K, Melhuish TM. Efficacy and adverse effects of buprenorphine in acute pain management: systematic review and meta-analysis of randomised controlled trials. Br J Anaesth. 2018;120(4):668\u201378.","journal-title":"Br J Anaesth"},{"key":"1432_CR46","unstructured":"Albaqami MS, Alqarni AA, Alabeesy MS, Alotaibi AN, Alharbi HA, Alshammari MM Buprenorphine for acute post-surgical pain: A systematic review and meta-analysis. Saudi J Anaesth., Hickey TR, Costa GPA, Oliveira D, Podosek A, Abelleira A, Avila-Quintero VJ et al. Buprenorphine versus full agonist opioids for acute postoperative pain management: a systematic review and meta-analysis of randomized controlled trials. Reg Anesth Pain Med. 2025."},{"key":"1432_CR47","doi-asserted-by":"crossref","unstructured":"Hickey TR, Costa GPA, Oliveira D, Podosek A, Abelleira A, Avila-Quintero VJ, et al. Buprenorphine versus full agonist opioids for acute postoperative pain management: a systematic review and meta-analysis of randomized controlled trials. Reg Anesth Pain Med. 2025.","DOI":"10.1136\/rapm-2024-106304"},{"key":"1432_CR48","doi-asserted-by":"crossref","unstructured":"Abelleira A, Hickey TR. Establishing buprenorphine for acute postoperative pain management. J Pain Palliat Care Pharmacother. 2025:1\u201312.","DOI":"10.1080\/15360288.2025.2524688"},{"issue":"Suppl 1","key":"1432_CR49","doi-asserted-by":"publisher","first-page":"s3","DOI":"10.1191\/0269216306pm1126oa","volume":"20","author":"A Dahan","year":"2006","unstructured":"Dahan A. Opioid-induced respiratory effects: new data on buprenorphine. Palliat Med. 2006;20(Suppl 1):s3\u20138.","journal-title":"Palliat Med"},{"issue":"1","key":"1432_CR50","doi-asserted-by":"publisher","first-page":"e0256752","DOI":"10.1371\/journal.pone.0256752","volume":"17","author":"LM Moss","year":"2022","unstructured":"Moss LM, Algera MH, Dobbins R, Gray F, Strafford S, Heath A, et al. Effect of sustained high buprenorphine plasma concentrations on fentanyl-induced respiratory depression: a placebo-controlled crossover study in healthy volunteers and opioid-tolerant patients. PLoS One. 2022;17(1):e0256752.","journal-title":"PLoS One"},{"key":"1432_CR51","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2021.103545","volume":"101","author":"P Bach","year":"2022","unstructured":"Bach P, Bawa M, Grant C, Milloy MJ, Hayashi K. Availability and use of non-prescribed buprenorphine-naloxone in a Canadian setting, 2014\u20132020. Int J Drug Policy. 2022;101:103545.","journal-title":"Int J Drug Policy"},{"issue":"5","key":"1432_CR52","first-page":"Online","volume":"95","author":"MF Raleigh","year":"2017","unstructured":"Raleigh MF. Buprenorphine maintenance vs. placebo for opioid dependence. Am Fam Physician. 2017;95(5):Online.","journal-title":"Am Fam Physician"},{"issue":"2","key":"1432_CR53","volume":"2014","author":"RP Mattick","year":"2014","unstructured":"Mattick RP, Breen C, Kimber J, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev. 2014;2014(2):CD002207.","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"1432_CR54","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1097\/ADM.0000000000001189","volume":"17","author":"LA Grande","year":"2023","unstructured":"Grande LA, Cundiff D, Greenwald MK, Murray M, Wright TE, Martin SA. Evidence on buprenorphine dose limits: a review. J Addict Med. 2023;17(5):509\u201316.","journal-title":"J Addict Med"},{"issue":"2","key":"1432_CR55","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/s12630-018-1255-3","volume":"66","author":"A Goel","year":"2019","unstructured":"Goel A, Azargive S, Lamba W, Bordman J, Englesakis M, Srikandarajah S, et al. The perioperative patient on buprenorphine: a systematic review of perioperative management strategies and patient outcomes. Can J Anaesth. 2019;66(2):201\u201317.","journal-title":"Can J Anaesth"},{"issue":"12","key":"1432_CR56","doi-asserted-by":"publisher","first-page":"3635","DOI":"10.1007\/s11606-020-06115-3","volume":"35","author":"M Buresh","year":"2020","unstructured":"Buresh M, Ratner J, Zgierska A, Gordin V, Alvanzo A. Treating perioperative and acute pain in patients on buprenorphine: narrative literature review and practice recommendations. J Gen Intern Med. 2020;35(12):3635\u201343.","journal-title":"J Gen Intern Med"},{"issue":"6","key":"1432_CR57","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1016\/j.mayocp.2019.10.007","volume":"95","author":"NS Warner","year":"2020","unstructured":"Warner NS, Warner MA, Cunningham JL, Gazelka HM, Hooten WM, Kolla BP, et al. A practical approach for the management of the mixed opioid agonist-antagonist buprenorphine during acute pain and surgery. Mayo Clin Proc. 2020;95(6):1253\u201367.","journal-title":"Mayo Clin Proc"},{"issue":"7","key":"1432_CR58","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1093\/pm\/pny217","volume":"20","author":"AN Quaye","year":"2019","unstructured":"Quaye AN, Zhang Y. Perioperative management of buprenorphine: solving the conundrum. Pain Med. 2019;20(7):1395\u2013408.","journal-title":"Pain Med"},{"issue":"5","key":"1432_CR59","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/j.annemergmed.2018.11.032","volume":"73","author":"AA Herring","year":"2019","unstructured":"Herring AA, Perrone J, Nelson LS. Managing opioid withdrawal in the emergency department with buprenorphine. Ann Emerg Med. 2019;73(5):481\u20137.","journal-title":"Ann Emerg Med"},{"key":"1432_CR60","unstructured":"Kumar R, Viswanath O, Saadabadi A, Buprenorphine. StatPearls. Treasure Island (FL): StatPearls Publishing."}],"container-title":["Current Pain and Headache Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11916-025-01432-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11916-025-01432-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11916-025-01432-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T07:03:55Z","timestamp":1770275035000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11916-025-01432-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,5]]},"references-count":60,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["1432"],"URL":"https:\/\/doi.org\/10.1007\/s11916-025-01432-w","relation":{},"ISSN":["1531-3433","1534-3081"],"issn-type":[{"value":"1531-3433","type":"print"},{"value":"1534-3081","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,5]]},"assertion":[{"value":"20 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"29"}}